Paper · 17545690
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
Kaurah P and 39 others. JAMA, 2007. Cited by 327 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. Papers, record 17545690. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17545690
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cadherins | Major topic |
| Founder Effect | Major topic |
| Germ-Line Mutation | Major topic |
| Stomach Neoplasms | Major topic |
| Adult | |
| Age of Onset | |
| Aged | |
| Aged, 80 and over | |
| Antigens, CD | |
| DNA Mutational Analysis | |
| Female | |
| Genetic Carrier Screening | |
| Genetic Counseling | |
| Haplotypes | |
| Heterozygote | |
| Humans | |
| Male | |
| Middle Aged | |
| Mutation | |
| Newfoundland and Labrador | |
| Pedigree | |
| Penetrance |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 5UO1 CA86389 | NCI NIH HHS | United States | U01CA086389 | PubMed and NIH |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 17,545,691 | Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. | https://conductscience.org/library/papers/17545691 | PubMed |
| Comment in | 17,983,818 | Hereditary diffuse gastric cancer: surveillance endoscopy is not enough to save lives. | https://conductscience.org/library/papers/17983818 | PubMed |
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by182
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 327 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,902,313 | Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41902313 | PubMed |
| 41,630,007 | Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41630007 | PubMed |
| 41,612,657 | Risk-Reducing Mastectomy in BRCA1/2 and Other High-Risk Gene Carriers: Current Evidence and Practical Guidance. | J Breast Cancer | 2026 | https://conductscience.org/library/papers/41612657 | PubMed |
| 41,591,723 | Hereditary diffuse gastric cancer with carcinogenesis from ectopic gastric mucosa in the duodenum. | Clin J Gastroenterol | 2026 | https://conductscience.org/library/papers/41591723 | PubMed |
| 41,023,738 | Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals. | Genome Biol | 2025 | https://conductscience.org/library/papers/41023738 | PubMed |
| 40,655,429 | Application of smart responsive nanomaterials in the theranostics of gastrointestinal malignancies: Current status and future perspectives. | Coord Chem Rev | 2025 | https://conductscience.org/library/papers/40655429 | PubMed |
| 40,243,654 | Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40243654 | PubMed |
| 40,225,916 | RNA Panel Sequencing Is an Effective Tool to Help Classify Splice Variants for Clinical Oncogenetic Diagnosis. | Hum Mutat | 2024 | https://conductscience.org/library/papers/40225916 | PubMed |
| 39,472,019 | Resolving complex duplication variants in autism spectrum disorder using long-read genome sequencing. | Genome Res | 2024 | https://conductscience.org/library/papers/39472019 | PubMed |
| 39,348,611 | A Decreased Appetite for Prophylactic Total Gastrectomy. | JCO Precis Oncol | 2024 | https://conductscience.org/library/papers/39348611 | PubMed |
1 to 10 of 182
See all 182 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| CDH1 | 999 | PubTator's text mining | https://conductscience.org/library/genes/999 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17545690
GET https://conductscience.org/api/papers/v1/17545690/authors?page=2